Text Size

A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale)

This study has been completed.
Sponsor:
Collaborators:
Eli Lilly and Company
Pudue Pharma
Shire Development LLC
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00885807
First received: April 20, 2009
Last updated: June 17, 2011
Last verified: June 2011
History of Changes

April 20, 2009
June 17, 2011
July 2006
April 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00885807 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale)
Psychometric Validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record in Patients With Attention-Deficit Hyperactivity Disorder

The purpose of the study is to evaluate the psychometric validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record. It is hypothesized that the Weiss Functional Impairment Rating Scale has strong psychometric properties and good convergent validity with other measures of functioning and discriminant validity from symptoms and quality of life.

The measures for this rating scale were developed at the request of the Canadian Attention Deficit Disorder Resource Alliance to provide clinician friendly tools free of charge as a way of improving screening for ADHD and comorbidity.

Patients are consented during clinic visits and agree to allow use of clinic data for the purpose of this research. They complete additional measure(s) for the purpose of the study. The data is then entered.

Internal consistency will be measured using Cronbach's alpha. Convergent, concurrent and discriminant validity will be measured using Pearson correlations. Domain reliability is determined with factor analysis. Up to 220 patients will be enrolled in the study.
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

People with ADHD from 7 years of age
Attention-Deficit/Hyperactivity Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
220
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Compliance to complete the WFIRS is key to inclusion.
Both
7 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00885807
H05-70402
No
Dr. Margaret Weiss, University of British Columbia
University of British Columbia
  • Eli Lilly and Company
  • Pudue Pharma
  • Shire Development LLC
Principal Investigator: Margaret D. Weiss, MD, Ph.D University of British Columbia
Study Director: Chistopher Gibbins, MD BC Children's & Women's Hospital, Vancouver
Study Director: Grant Iverson, MD University of British Columbia
Study Director: Brian Brooks, MD BC Children's & Women's Hospital, Vancouver
Study Director: Li Ying Lu, MD BC Children's & Women's Hospital, Vancouver
University of British Columbia
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP